Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Chronic Sialorrhea Market Size, Drug Pipeline Developments and Investment Trends 2024–2034The 7 major chronic sialorrhea markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.15% during 2024-2034.
By: IMARC Group According to the IMARC Group, The 7 major chronic sialorrhea markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.15% during 2024-2034. This can be attributed to the rising popularity of transoral endoscopic submandibular ganglion neurectomy, since it can provide symptom relief in patients who have failed traditional pharmacological therapies. Chronic sialorrhea represents a nerve and muscle condition that causes an unintentional loss of saliva from the mouth. The chronic sialorrhea market is expanding due to the increasing prevalence of neurological conditions, which is driving the demand for effective treatments. Besides this, the growing awareness of the significant impact of this illness on quality of life and its social and physical complications is encouraging patients to seek medical care, further augmenting the chronic sialorrhea market growth. Advancements in pharmacological treatments, such as botulinum toxin injections and anticholinergic medications, are providing effective symptom relief. Moreover, the development of novel therapies, including long-acting botulinum toxin formulations, is improving treatment durability and reducing the frequency of interventions, thereby catalyzing the chronic sialorrhea market expansion. Request for a sample of this report: https://www.imarcgroup.com/ Countries Covered:
The competitive landscape of the chronic sialorrhea market has been studied in the report with the detailed profiles of the key players operating in the market. 1. Merz Pharma 2. Supernus Pharmaceuticals 3. Shionogi Explore the Full Report with TOC: Chronic Sialorrhea (https://www.imarcgroup.com/ If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization. About Us: IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. Contact US: IMARC Group 134 N 4th St. Brooklyn, NY 11249, USA Email: sales@imarcgroup.com Tel No:(D) +91 120 433 0800 United States: +1-631-791-1145 End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number